The Indian pharmaceutical industry is one of the most resilient and high-growth industries. Pharma stocks held relative strength versus the broader indices even in 2026 amid market volatility. India is a global leader in generic drug manufacturing. As a country, India contributes nearly 20% of global supply by volume, with exports worth $30 billion annually.

Global demand, steady growth, and innovation in this industry makes it more attractive for investors.

Top high-growth pharma stocks in India (2026)

Below are some of the most promising pharma stocks based on recent performance, fundamentals, and growth trends.

Sun Pharmaceutical Industries

Sun Pharma is the largest pharmaceutical company in India with a strong global presence across more than 100 countries. The company has built a diversified portfolio that includes generics, speciality drugs, and branded formulations. Its focus on high-margin speciality products in the US market has significantly improved profitability in recent years.

Companies latest data:

• Market Cap: ₹3,88,846 Cr.
• 1-year return: -10%
• 3-year return: 19%
• 5-year return: 20%
• ROE: 16.9%
• Dividend Yield: 0.99%

Divi’s Laboratories

Divi’s Laboratories is a leading manufacturer of active pharmaceutical ingredients (APIs) and intermediates, supplying to major global pharma companies. The company operates on a high-margin, export-driven business model with long-term contracts. It is known for its strong compliance standards and cost-efficient manufacturing. Traders monitor the Divis Lab share price to capture opportunities. 

latest insights:

• Market Cap: ₹1,68,871 Cr.
• 1-year return: 2%
• 3-year return: 25%
• 5-year return: 11%
• ROE: 15.4%
• Dividend Yield: 0.47%

Torrent Pharmaceuticals

Torrent Pharma is known for its branded generics with a strong presence in India and international markets. The company has a leadership position in therapies like cardiovascular, central nervous system, and gastrointestinal segments. It focuses on high-margin branded products rather than low-margin generics.

Latest market data:

• Market Cap: ₹1,39,393 Cr.
• 1-year return: 24%
• 3-year return: 36%
• 5-year return: 27%
• ROE: 26%
• Dividend Yield: 0.78%

Laurus labs

Laurus Labs is a rapidly growing pharmaceutical company focused on APIs, formulations, and contract manufacturing. It has a strong presence in antiretroviral drugs and is expanding into oncology and other high-growth segments. The company benefits from increasing global demand and long-term supply agreements.

Laurus Labs' latest data:

• Market Cap: ₹60,121 Cr.
• 1-year return: 72%
• 3-year return: 56%
• 5-year return: 19%
• ROE: 7.45%
• Dividend Yield: 0.11%

Glenmark Pharmaceuticals

Glenmark Pharma is an innovation-driven company, particularly in offering respiratory and dermatology solutions. The firm has widened its footprint across the regulated markets of the US and Europe. It also invests in specialty and branded formulations for margin improvement. 

Latest market data:

• Market Cap: ₹64,892 Cr.
• 1-year return: 69%
• 3-year return: 64%
• 5-year return: 33%
• ROE: 15.8%
• Dividend Yield: 0.11%

Mankind pharma

Mankind Pharma has a dominant presence in the Indian domestic market, especially in acute and chronic therapies. The company focuses on affordability and strong distribution, which gives it a competitive edge. It has been expanding its presence in high-growth chronic segments like cardiology and diabetes.

Latest market data:

• Market Cap: ₹93,605 Cr.
• 1-year return: -11%
• ROE: 14.7%
• Dividend Yield: 0.04%

Conclusion

India’s pharma industries are seen as a high-potential opportunity for the long term. It has a strong export demand and favourable government policies, due to which the sector will continue to move upward.  Companies like Sun Pharma, Divi’s Labs, Torrent Pharma, and Laurus Labs are considered leaders in high growth stocks.

Although pharma stocks come with strong growth potential, they have certain risks, such as regulatory approvals and compliance issues, price pressure in global markets, and currency fluctuations. As an investor, these risks must be taken into account before investing.